Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

PM Images Regeneron's Q2 Surge: Blockbuster Drugs Drive Revenue Growth Regeneron (NASDAQ:REGN) is up another 13% since my most recent "buy" recommendation in March. Seeking Alpha My last article covered Q4 '2023 earnings, which revealed strong performances from blockbuster drugs like Eylea, Libtayo, and Dupixent. In Q2 2024, it was more of the same for the $100 billion-plus pharmaceutical giant. Revenue grew 12% year-over-year, reaching $3.55 billion. The growth was, again, inspired by strong performances f ...